ESH 2019 | How do genomic and epigenomic alterations synergize in AML?

The AML Global Portal were delighted to speak to Lars Bullinger, Charite University Hospital Berlin, Berlin, DE, during the European School of Hematology (ESH) Translational Research Conference on AML. We asked Lars Bullinger: How do genomic and epigenomic alterations synergize in AML?

He explained that epigenetic mutations often predispose to leukemic events. This is why new technologies such as NGS will become part of clinical routine so that we can detect biomarkers  predicting response to more targeted therapies such as hypomethylating agents or FLT3 inhibitors.